Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

Leukemia. 2017 Oct;31(10):2247-2251. doi: 10.1038/leu.2017.217. Epub 2017 Jul 10.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anthracyclines / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / therapeutic use
  • Female
  • Hematopoietic Stem Cells / drug effects
  • Humans
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Nuclear Proteins / genetics*
  • Nucleophosmin

Substances

  • Anthracyclines
  • NPM1 protein, human
  • Nuclear Proteins
  • Cytarabine
  • Nucleophosmin